摘要
分化型甲状腺癌经规范治疗总体预后良好,然而当其失分化为碘难治性甲状腺癌(RAIR-DTC)时,往往疾病进展迅速、病死率高,且目前治疗方法有限。近年来,随着对RAIR-DTC发生发展相关基因突变、信号传导通路、免疫微环境研究的日益深入以及新型核素示踪剂的研发,为其靶向治疗提供了更多的理论依据。
Differentiated thyroid cancer(DTC)generally carries good prognosis through standard treatment.While,it could dedifferentiate into radioiodine refractory differentiated thyroid cancer(RAIR-DTC),which progresses rapidly with high mortality and limited treatment methods.Recently,along with the increasing of studies on genetic features,signal transduction pathways and immune microenvironment of RAIR-DTC,as well as the development of new radionuclide tracers,more theoretical bases have been provided for the targeted therapy of RAIR-DTC.
作者
刘延晴
林岩松
LIU Yan-qing;LIN Yan-song(Department of Nuclear Medicine,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,Beijing 100730,China)
出处
《中国实用外科杂志》
CSCD
北大核心
2019年第3期216-220,共5页
Chinese Journal of Practical Surgery
基金
国家自然科学基金资助项目(No.81571714
No.81771875)
亚洲-太平洋甲状腺研究组~~
关键词
碘难治性分化型甲状腺癌
靶向治疗
免疫疗法
肽受体介导的放射性核素治疗
radioiodine refractory differentiated thyroid cancer
targeted therapy
immunotherapy
peptide receptor radionuclide therapy
